UK Markets closed

Frontline Ltd. (0REH.L)

YHD - YHD Delayed price. Currency in USD
Add to watchlist
809,734,016.00+7.09 (+0.00%)
As of 06:07PM EDT. Market open.
Full screen
Previous closeN/A
YTD returnN/A
Expense ratio (net)N/A
CategoryN/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability ratingN/A
Net assetsN/A
Beta (5Y monthly)N/A
YieldN/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • Simply Wall St.

    Frontline's (NYSE:FRO) investors will be pleased with their notable 64% return over the last five years

    It might be of some concern to shareholders to see the Frontline Ltd. ( NYSE:FRO ) share price down 10% in the last...

  • Globe Newswire

    Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy

    Five abstracts accepted with new research and technology insights and data to further enhance AAV-based gene therapy candidatesLONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that will take place May 16-19, 2022 in Washington, D.C. The presentations will provide new insights and data

  • Globe Newswire

    FRO - Changes to the Board composition

    Frontline Ltd. (“Frontline” or “the Company”) announces that Mr. Tor Svelland has resigned as a Director of the Company. Mr. Svelland has served as a Director since August 2020. The Board would like to thank Mr. Svelland for his contribution and wishes him well in his future pursuits. Frontline announces the appointment of Mr. Ole B. Hjertaker as a Director of the Company. Ole B. Hjertaker has been a Director of SFL Corporation Ltd. (“SFL”) since October 2019. Mr. Hjertaker has served as Chief E